AUTL Autolus Therapeutics plc

12.24
+0.19  (+2%)
Previous Close 12.05
Open 12.43
Price To Book 1.85
Market Cap 550,584,307
Shares 44,982,378
Volume 182,337
Short Ratio
Av. Daily Volume 285,691
Stock charts supplied by TradingView

NewsSee all news

  1. Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  2. Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

  3. Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

    LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  4. Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  5. Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data due 2H 2020.
AUTO4
T-cell lymphoma
Phase 1 interim data due at ASH December 7, 2019 at 3:15 PM. Phase 2 decision on initiation in DLBCL is expected for mid-2020
AUTO3 - (ALEXANDER)
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1 data due at ASH December 8, 2019 at 6PM ET.
AUTO2
Relapsed or refractory multiple myeloma
Phase 2 trial to be initiated 2H 2019. Updated Phase 1 data due at ASH December 7, 2019 at 2:45 PM ET.
AUTO1
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Phase 1 data due at ASH December 8, 2019 at 6PM ET.
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia
Phase 1/2 trial to be initiated 2H 2020.
AUTO6
Neuroblastoma

Latest News

  1. Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today

  2. Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

  3. Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

    LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  4. Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  5. Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

    LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced

  6. Autolus Therapeutics to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7

    LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release

  7. Autolus Announces Changes to Executive Leadership Team

    LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced changes to the

  8. Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical

  9. Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

    Findings from Phase I CARPALL Trial Demonstrate that Autolus' Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a

  10. Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

    LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will